Language selection

Search

Details for: ZYPREXA

Company: ELI LILLY CANADA INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02229250ZYPREXAOLANZAPINE2.5 MGTABLETORAL
02229269ZYPREXA - 5MGOLANZAPINE5 MGTABLETORAL
02243086ZYPREXA ZYDISOLANZAPINE5 MGTABLET (ORALLY DISINTEGRATING)ORAL
02229277ZYPREXAOLANZAPINE7.5 MGTABLETORAL
02229285ZYPREXA - 10MGOLANZAPINE10 MGTABLETORAL
02247099ZYPREXA INTRAMUSCULAROLANZAPINE (OLANZAPINE TARTRATE)10 MG / VIALPOWDER FOR SOLUTIONINTRAMUSCULAR
02243087ZYPREXA ZYDISOLANZAPINE10 MGTABLET (ORALLY DISINTEGRATING)ORAL
02238850ZYPREXA 15MGOLANZAPINE15 MGTABLETORAL
02243088ZYPREXA ZYDISOLANZAPINE15 MGTABLET (ORALLY DISINTEGRATING)ORAL
02243089ZYPREXA ZYDISOLANZAPINE20 MGTABLET (ORALLY DISINTEGRATING)ORAL
02238851ZYPREXA 20MGOLANZAPINE20 MGTABLETORAL
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
Summary Safety Review - Atypical Antipsychotics - Liver failure
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: